Cytarabine - Wikipedia
AGO_2022D_14_Supportive Therapie und NW-Management_REF
AGO_2022E_14_Supportive Care and Managment of Side Effects_MASTER_schwarz_final
Inhaled Medicines: Past, Present, and Future | Pharmacological Reviews
Kriterien zur Bestimmung der zweckmäßigen Vergleichstherapie und Recherche und Synopse der Evidenz zur Bestimmung der zweckmä
Pharmacotherapy in Children and Adolescents: Oncology | SpringerLink
Anhang
Evaluation of allogeneic Transplantation in Patients above the age of 60 years with High Risk Acute Myeloid Leukemia (ETAL-2)
MATRIX / High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS ly
AGO_2022D_14_Supportive Therapie und NW-Management_REF
Inhaled Medicines: Past, Present, and Future | Pharmacological Reviews
Janus-Type Dendrimers Based on Highly Branched Fluorinated Chains with Tunable Self-Assembly and 19F Nuclear Magnetic Resonance Properties | Macromolecules
AGO_2022E_14_Supportive Care and Managment of Side Effects_MASTER_schwarz_final
Pharmacotherapy in Children and Adolescents: Oncology | SpringerLink
Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine
Kriterien zur Bestimmung der zweckmäßigen Vergleichstherapie und Recherche und Synopse der Evidenz zur Bestimmung der zweckmä
Folie 1
![20/2010, 16-31 October - Fachinformationsverbund "Internationale ...](https://img.yumpu.com/20985269/1/500x640/20-2010-16-31-october-fachinformationsverbund-quotinternationale-.jpg "20/2010, 16-31 October - Fachinformationsverbund "Internationale ...")
20/2010, 16-31 October - Fachinformationsverbund "Internationale ...
Pharmacotherapy in Children and Adolescents: Oncology | SpringerLink
Kriterien zur Bestimmung der zweckmäßigen Vergleichstherapie und Recherche und Synopse der Evidenz zur Bestimmung der zweckmä
MATRIX / High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS ly
Pharmacotherapy in Children and Adolescents: Oncology | SpringerLink
AGO_2022D_14_Supportive Therapie und NW-Management_REF
